AXIS: activity after progression on sunitinib
1.0
Median PFS (months)
Axitinib
4.8 (95% CI 4.5–6.4)
Sorafenib
3.4 (95% CI 2.8–4.7)
0.8
ee survival
IRC assessment
0.4
0.6
f progression‐fr
HR=0.741; 95% CI 0.573–0.958; p=0.010
0.2
Probability o
0.0
0
2
4
8
20
Months
6
18
10
12
14
16
PFS by investigator: 6.5 to 4.5 months with axitinib vs sorafenib, p=0.0002
Rini et al. Lancet 2011
